InvestorsReplenish NutrAI
We're bootstrapped. Without outside capital, we've built peer-reviewed research, a working app and a global team. We're building with partners who share our mission.
01The problem
The research that could answer that question exists. It sits in published clinical trials and peer-reviewed journals, behind paywalls and medical jargon. So people guess, and the industry sells to the guess.
02Why it matters
690 million women worldwide are between the ages of 45 and 59, when menopause typically occurs.
They are our first users, and the first of many groups we plan to serve. See where they live →
Source: WorldPop (2025), age and sex structures R2025A, 2026 estimates.
03Built without outside capital
An app that checks supplements ingredient by ingredient against published clinical trials, answers questions with sources and puts symptoms in the context of the local environment. In testing on iOS and Android.
Our team's review in Clinical Immunology Communications ↗, published by Elsevier.
Product doses compared, one by one, against the doses studied in clinical trials, and mapped to symptoms.
Crisis and urgent-symptom routing, medication and cancer-history checks, and language rules that never claim a supplement treats or cures.
Research, engineering and design across the United States, Europe and Asia. Meet the team →
04Business model
Scanning, answers with sources and safety warnings. The way in, and the proof of our mission.
Symptom tracking, monthly health reports, doctor visit export and personal history, after a 14-day free trial.
The evidence behind supplement decisions, for the wider industry.
05Where we're going
The same method across the whole supplement industry: for women, men and children, in the Americas, Africa, Europe, the Middle East and Asia.
We'll send our deck and set up a conversation.